Catalyst Biosciences
Graphic

OVERVIEW

Catalyst has leveraged its leading protease engineering technologies to build a portfolio of novel therapeutic candidates focused in the fields of hemostasis and complement regulation. 

Our successful protease product discovery engine has enabled us to design and develop lead candidates that have favorable pharmaceutical properties and effectively intervene against attractive therapeutic targets that are intractable to small molecules or antibodies. 

Catalyst’s lead programs in the areas of hemophilia and complement hold potential for early clinical proof-of-concept in patients in Phase 1 studies and accelerated approval paths.

Learn more about Catalyst’s product candidates:
Click here for hemostasis candidates.
Click here for complement candidates.


Catalyst Bioscience Protease Pipeline